Does Bacillus coagulans GBI-30, 6086 reduce TNF-α? Evidence review
This conversation examines whether Bacillus coagulans GBI-30, 6086 helps reduce tumor necrosis factor alpha (TNF-α). Based on a 2014 randomized controlled trial in chronic HIV-1 patients, the evidence shows no significant effect, classifying the outcome as neutral.
Does Bacillus coagulans GBI-30, 6086 help reduce tumor necrosis factor alpha, or is there not really any evidence for that?
Based on the research in Pillser's database, the evidence does not support that Bacillus coagulans GBI-30, 6086 reduces tumor necrosis factor alpha (TNF-α).
Here's the relevant finding:
- 1 randomized controlled trial (2014) examined this specific probiotic strain's effect on TNF-α in patients with chronic HIV-1 infection. The study concluded: "None of the biomarkers showed significant changes on probiotic treatment or between-group differences in change."1 The effect was classified as neutral — neither beneficial nor harmful.2
So, to directly answer your question — no, there isn't evidence that this strain reduces TNF-α. Only one study has been conducted on this specific outcome, and it found no significant effect.
Footnotes
-
"Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial" (2014) — Pillser ↩
-
Pillser research database, Bacillus coagulans GBI-30, 6086 and Reduced Tumor Necrosis Factor Alpha ↩